导航
| 统计阶段 | 收益率 | 同类排名 |
|---|---|---|
| 今年以来 | 2.94% | 1473/4773 |
| 近一周 | 0.79% | 55/5462 |
| 近一月 | 5.70% | 41/5421 |
| 近一季 | 5.29% | 281/5209 |
| 近半年 | 6.42% | 687/4920 |
| 近一年 | 4.04% | 1808/4366 |
| 近两年 | 41.52% | 1814/2954 |
| 近三年 | 51.18% | 518/2253 |
| 成立以来 | 81.38% | - |
| 年份 | 年收益 | 1季度 | 2季度 | 3季度 | 4季度 |
| 2026 | - - |
-2.67% 2858/4961 |
-7.86% 3809/5312 |
- - |
- - |
| 2025 | 11.24% 2756/4813 |
2.71% 1287/3635 |
11.70% 141/4076 |
-8.25% 4027/4524 |
5.68% 411/4813 |
| 2024 | 39.81% 19/3463 |
10.10% 74/2808 |
6.86% 120/3014 |
12.52% 2325/3129 |
5.61% 584/3463 |
| 2023 | -2.26% 568/2656 |
-2.42% 1978/2280 |
1.66% 205/2385 |
5.03% 103/2515 |
-6.18% 1659/2655 |
| 2022 | -4.03% 77/2207 |
2.33% 58/1919 |
-1.27% 1696/2016 |
-8.11% 169/2113 |
3.37% 708/2208 |
| 2021 | 0.61% 710/1822 |
10.19% 43/1255 |
-1.91% 1182/1330 |
-6.53% 950/1466 |
-0.42% 1234/1822 |
| 2020 | 9.64% 841/1250 |
-11.95% 863/1028 |
4.30% 911/1067 |
7.57% 773/1164 |
10.99% 572/1184 |
| 2019 | 27.86% 530/1092 |
15.73% 681/754 |
2.65% 77/804 |
0.07% 562/850 |
7.55% 424/918 |
| 2018 | -10.87% 73/834 |
- - |
- - |
- - |
-8.99% 114/691 |
| 2017 | 18.28% 209/714 |
- - |
- - |
- - |
- - |
| 2016 | 0.61% 101/605 |
- - |
- - |
- - |
- - |
| 2015 | - - |
- - |
- - |
- - |
- - |
| 2014 | - - |
- - |
- - |
- - |
- - |
| 2013 | - - |
- - |
- - |
- - |
- - |
| 2012 | - - |
- - |
- - |
- - |
- - |
| 基金名称 | 最新净值 | 季增长率 |
| 万家中证港股通创新药ETF | 1.5896 | 28.31% |
| 景顺长城中证港股通创新药ETF | 1.6507 | 28.23% |
| 港股医疗 | 0.9366 | 28.18% |
| 港股医疗ETF | 1.4282 | 28.15% |
| 港股通医疗ETF工银 | 0.9464 | 28.06% |
| 港股通医疗ETF华宝 | 0.9577 | 27.97% |
| 天弘恒生沪深港创新药精选50ETF发起联接C | 1.2844 | 27.92% |
| 天弘恒生沪深港创新药精选50ETF | 0.8437 | 27.35% |
| 万家中证港股通创新药ETF发起式联接A | 1.3863 | 27.32% |
| 万家中证港股通创新药ETF发起式联接C | 1.3856 | 27.27% |
| 易方达中证银行ETF联接(LOF)A VS. 长安沪深300非周期A(740101) |